Company intelligence / Profile preview

SignalChem Biotech

Richmond, British Columbia, Canada

Ownership: Private
Development stage: Other

Overview

SignalChem Biotech was a global leader in recombinant cell signaling proteins, kinases, and bioreagents with advanced contract research services; it initiated a clinical-stage oncology pipeline focused on kinase inhibitors. The company became a key asset of Sino Biological in 2024. Clinical data on its proprietary drugs is limited in public sources; main programs such as SLC-391 (AXL inhibitor) reached clinical stages.

Therapeutic areas: ImmunologyMetabolic DisordersInfectious DiseasesCardiovascularOncologyNeurology
Modalities: Recombinant proteinSmall moleculeAntibodysiRNAEnzymePeptides
Industry: Biotech

Partnerships

Various CRO relationshipsPartnerships with pharmaceutical companies and academics for kinase inhibitor profiling and drug discovery

Beyond the preview

Go deeper on SignalChem Biotech.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SignalChem Biotech.

Explore the full profile